Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness

Cancer Gene Therapy

Volumn 6, Issue 5, 1999, Pages 447-455

  Govaerts, Anne Sophie ^a   Guillaume, Thierry ^b   André, Marc ^b   Bayat, Babak ^b   Feyens, Anne Marie ^b   Hawley, Teresa S ^b   Fong, A Z C ^b   Hawley, Robert G ^b   Symann, Michel ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NONE

Author keywords

Cancer gene therapy; Interleukin 12; Interleukin 2; Tumor immunotherapy

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; PRIMER DNA;

ANIMAL; ARTICLE; C57BL MOUSE; EXPERIMENTAL MELANOMA; FIBROBLAST; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; RETROVIRUS;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; FIBROBLASTS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERLEUKIN-12; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RETROVIRIDAE;

EID: 0033193128     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700064     Document Type: Article

References (51)

1. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immimol. 1995;13:399-415.
2. Musiani P, Modesti A, Giovarelli M, et al. Cytokines, tumour-cell death, and immunogenicity: a question of choice. Immunol Today. 1997;18:32-36.
3. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
4. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 1994;54:6022-6026.
5. Tepper RI, Mulé JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:153-164.
6. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
7. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808-6812.
8. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for NK cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and NK cells. J Immunol. 1991;146:3074-3081.
9. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med. 1992; 176:1387-1398.
10. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med. 1993;177:1199-1204.
11. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today. 1993;14:335-338.
12. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991;173:869-879.
13. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic activity and induces production of IFN-γ in vivo. Int Immunol. 1993;6:157-167.
14. + T lymphocytes. J Immunol. 1993;151:2444-2452.
15. Robertson MJ, Soiffer RJ, Wolf SF, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992;175:779-788.
16. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-586.
17. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
18. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153: 1697-1706.
19. Coughlin CM, Wysocka M, Kurzawa HL, et al. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 1995;55:4980-4987.
20. Wiggington JM, Komschlies KL, Back TC, et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst. 1996;88:38-43.
21. Mu J, Zou JP, Yamamoto N, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995;55:4404-4408.
22. Vagliani M, Rodolfo M, Cavallo F, et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res. 1996;56: 467-470.
23. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA. 1996;93:11798-11801.
24. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines. J Immunol. 1996;156:3357-3365.
25. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997;89:1049-1058.
26. Fallarino F, Uyttenhove C, Boon T, Gajewski F. Endogenous IL-12 is necessary for rejection of P815 variants in vivo. J Immnnol. 1996;156:1095-1100.
27. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 1996;56:2531-2534.
28. Desai BB, Quinn PM, Wolitzky AG, et al. The IL-12 receptor: distribution and regulation of receptor expression. J Immunol. 1992;148:3125-3132.
29. Hawley RG, Lieu FHL, Fong AZC, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
30. Lieu FHL, Hawley TS, Fong AZC, Hawley RG. Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy. Cancer Gene Ther. 1997;4:167-175.
31. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating the viral genes on two different plasmids. J Virol. 1988;62:1120-1124.
32. Williams DA, Orkin SH, Mulligan RC. Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vino. Proc Natl Acad Sci USA. 1986;83:2566-2570.
33. Gately MK, Chizzonite R, Presky DH. Measurement of human and mouse interleukin-12. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. New York: Wiley and Sons; 1995:Unit 6.16.1-6.16.4.
34. Plautz GE, Yang ZY, Wu BY, et al. Immunotherapy of malignancy by in vivo gene transfer in tumors. Proc Natl Acad Sci USA. 1993;90:4645-4649.
35. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
36. Fakhrai H, Shawler DL, Gjerset R, et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther. 1995;6:591-601.
37. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol. 1995;155:1393-1403.
38. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypass T helper function in generation of an antitumor response. Cell. 1990;60: 397-403.
39. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
40. Economou JS, Hoban M, Lee JD, et al. Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother. 1991;34:49-52.
41. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-γ production. Blood. 1997; 90:2541-2548.
42. Bree AG, Schlerman FJ, Kavaini MD, et al. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun. 1994;204:1150-1157.
43. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3:409-417.
44. Gulber U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA. 1991;88:4143-4147.
45. Belsham J. Dual initiation sites of protein synthesis on foot-and-mouth disease virus RNA are selected following internal entry and scanning of ribosomes in vivo. EMBO J. 1992;11:1105-1110.
46. Jang SK, Wimmer E. Cap-independent translation of encephalomyocarditis virus RNA: structural elements of the internal ribosomal entry site and involvement of a cellular 57-kDa RNA-binding protein. Genes Dev. 1990;4: 1560-1572.
47. Zitvogel L, Tahara H, Cai Q, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther. 1994; 5:1493-506.
48. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CDS-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol. 1995;25:137-146.
49. Yang G, Mizuno MT, Hellström KE, Chen L. B7-negative versus B7-positive P815 tumor. J Immumol. 1997;158: 851-858.
50. Schmitt M, Ikeda H, Nagata Y, et al. Involvement of T-cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes, Int J Cancer. 1997;72:505-511.
51. Tannenbaum CS, Wicker N, Armstrong D, et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol. 1996;156:693-699.